Standard therapy for the treatment of malignant pleural mesothelioma. New agents in the management of advanced mesothelioma. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Multimodality therapy in mesothelioma: role of chemotherapy. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. |
Chemotherapy - Mesothelioma
Believe in a Cure!
Contact us for a free copy of the book "100 Questions & Answers about mesothelioma."
(877) END-MESO
(877) 363-6376


